Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD19 CAR-T cells (University of Utah)
- Development stage
- Unknown
- Lead developer
- University of Utah
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T cells (University of Utah) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory CD19-positive B-cell malignancies, including non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The therapy utilizes a second-generation CAR construct consisting of a murine anti-human CD19 single-chain variable fragment (scFv) derived from the FMC63 clone, linked to a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain. A notable feature of this program is the use of the Miltenyi Biotec CliniMACS Prodigy platform for automated, closed-system manufacturing (CellReGen process), which incorporates a transmembrane domain derived from TNFRSF19. This approach is designed to improve the consistency and scalability of CAR-T production within an academic clinical setting.
- Other names
- Anti-CD19 CAR-T cellsAnti-CD-19 CAR-T cellsAnti-CD 19 CAR-T cellsUU-CD19-CAR-TUU-CD-19-CAR-TUU-CD 19-CAR-TCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cells
02
Targets
Beyond the preview
Go deeper on Anti-CD19 CAR-T cells (University of Utah).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD19 CAR-T cells (University of Utah).